METHODS FOR THE IDENTIFICATION OF AGENTS THAT MODULATE THE STRUCTURE AND PROCESSING OF A MEMBRANE BOUND PRECURSOR PROTEIN
(19)AUSTRALIAN PATENT OFFICE(54)TitleMETHODS FOR THE IDENTIFICATION OF AGENTS THAT MODULAI b THE STRUCTURE ANDPROCESSING OF A MEMBRANE BOUNDPRECURSOR PROIbIN(21) Application No: 2003287524 (22) Application Date: 2003.11.04(87) WIPONo: WO04/042074 (30) Priority Data (31) Number (32) Date (33) Country60/424,030 2002.11.04US(43) Publication Date : 2004.06.07 (43) Publication Journal Date : 2004.07.01(71) Applicant(s) ICOGEN CORPORATION(72)Inventor(s)HAGEN, Frederick S., (H) Application NoAU2003287524 A1(19)AUSTRALIAN PATENT OFFICE(54)TitleMETHODS FOR THE IDENTIFICATION OF AGENTS THAT MODULAI b THE STRUCTURE ANDPROCESSING OF A MEMBRANE BOUNDPRECURSOR PROIbIN(21) Application No: 2003287524 (22) Application Date: 2003.11.04(87) WIPONo: WO04/042074 (30) Priority Data (31) Number (32) Date (33) Country60/424,030 2002.11.04US(43) Publication Date : 2004.06.07 (43) Publication Journal Date : 2004.07.01(71) Applicant(s) ICOGEN CORPORATION(72)Inventor(s)HAGEN, Frederick S., The present invention provides methods for the screening and identification of agents from a large library of molecular structures that can alter the cleavage of a membrane protein of interest. Agents identified by the methods of the present invention that modify the cleavage of the membrane protein can be used in the treatment and prevention of diseases such as inflammation, diabetes, cancer, Alzheimer's disease, Parkinson's disease, and the like. The methods select for and identify effector agents that bind to the membrane protein of interest causing a structural change in the structure of the membrane protein in such a way that the efficiency of the cleavage of a secretase is modulated. Further, the methods are carried out in an in vivo system that provides for physiological conditions similar or identical to conditions for membrane protein processing. Agents can be selected for their ability to cause a decrease or increase the amount of secretase cleavage of the membrane protein. WHAT IS CLAIMED IS: 1. A method for identifying an agent that alters processing of a membrane protein of interest, comprising: contacting the agent with an animal host cell that expresses the membrane protein and at least one processing enzyme of the membrane protein, and detecting altered processing of the membrane protein to identify the agent that alters the processing of the membrane protein 2. The method of claim 1, wherein detecting the altered membrane protein processing comprises assessing the relative presence or absence of at least one species of membrane protein fragment on the surface of the host cell or released from the surface of the host cell.
3. The method of claim 2, wherein the at least one species of membrane protein fragment is released from the surface of the host cell.
4. The method of claim 1, wherein the at least one membrane protein processing enzyme is a protease or a phospholipase.
5. The method of claim 1, wherein the altered membrane protein processing results in a decreased production of a fragment of the membrane protein released from the cell surface.
6. The method of claim 5, wherein the released fragment is associated with an increased risk of disease.
7. The method of claim 6, wherein the disease is an inflammatory disease, cancer, diabetes, Alzheimer's disease, or Parkinson's disease.
8. The method of claim 1, wherein the agent is from a compound library. <Desc/Clms Page number 56> 9. The method of claim 8, wherein the compound library is a combinatorial chemical library.
10. The method of claim 8, wherein the compound library is a natural products library.
11. The method of claim 8, wherein the compound library is a peptide library.
12. The method of claim 1, wherein the agent is a small molecule.
13. The method of claim 1, wherein the agent is a biomolecule.
14. The method of claim 13, wherein the biomolecule is a peptide.
15. The method of claim 14, wherein the peptide is produced by transcription and translation from an oligonucleotide encoding the peptide.
16. The method of claim 15, wherein the oligonucleotide has a length of about 18 to about 120 nucleotides.
17. The method of claim 15, wherein the oligonucleotide has a length of about 36 to about 60 nucleotides.
18. The method of claim 15, wherein contacting the peptide with the host cell comprises introducing an expression vector, the expression vector comprising the oligonucleotide encoding the peptide, into the host cell, the host cell thereby expressing and displaying the peptide within a secretory pathway and on an extracellular cell surface.
19. The method of claim 15, wherein the oligonucleotide is from an expression library comprising a plurality of oligonucleotides, at least of majority of the oligonucleotides having different sequences encoding a different peptide.
20. The method of claim 19, wherein the sequence of the plurality of oligonucleotides is randomized.
21. The method of claim 19, wherein the expression library is pre- <Desc/Clms Page number 57> enriched for oligonucleotides encoding peptides that specifically bind to the membrane protein.
22. The method of claim 19, wherein the contacting of the peptide with the host cell comprises introducing the expression library into a first plurality of animal host cells that express the membrane protein and at least one processing enzyme of the membrane protein, the host cells thereby expressing and displaying the different peptides within a secretory pathway and on an extracellular cell surface.
23. The method of claim 22, further comprising: selecting from the first plurality of host cells displaying the different peptides a first subset of host cells that exhibit altered membrane protein processing; and identifying from the first subset of host cells a first sub-library of the expression library comprising at least one oligonucleotide that encodes the peptide that alters the processing of the membrane protein.
24. The method of claim 22, wherein the first plurality of host cells displaying the different peptides have been enriched using a selectable marker.
25. The method of claim 24, wherein the selectable marker is V5, FLAG, or thioredoxin.
26. The method of claim 24, wherein the enrichment comprises magnetic bead selection.
27. The method of claim 24, wherein the enrichment comprises selection by fluorescence-activated cell sorting.
28. The method of claim 24, wherein the host cells expressing and displaying the different peptides on the extracellular cell surface express a high copy number of the different peptides.
29. The method of claim 15, wherein the peptide is displayed as a fusion protein with a presentation molecule. <Desc/Clms Page number 58> 30. The method of claim 29, wherein the presentation molecule is CD24.
31. The method of claim 29, wherein the presentation molecule is IL-3 receptor.
32. The method of claim 29, wherein the presentation molecule is thioredoxin.
33. The method of claim 29, wherein the fusion protein further comprises a marker epitope.
34. The method of claim 33, wherein the marker epitope is polyhistidine, V5, FLAG, or myc 35. The method of claim 29, wherein the fusion protein further includes a signal for a glycophosphatidylinositol (GPI) anchorage.
36. The method of claim 1, wherein the animal host cell is a mammalian host cell.
37. The method of claim 1, wherein the animal host cell is a recombinant host cell.
38. The method of claim 37, wherein the animal host cell is an isolated cell.
39. The method of claim 1, wherein the agent is contacted with the host cell under substantially physiological conditions.
40. The method of claim 39, wherein the substantially physiological conditions comprise the presence of a complex biological fluid.
41. The method of claim 40, wherein the complex biological fluid is blood, serum, plasma, or cerebral spinal fluid (CSF).
42. The method of claim 2, wherein the assessment of the relative <Desc/Clms Page number 59> presence or absence of at least one species of a membrane protein fragment on the cell surface comprises contacting the host cell with at least one detectably labeled marker that specifically binds to the at least one species of membrane fragment and detecting the bound, labeled marker.
43. The method of claim 42, wherein the at least one marker is an antibody that binds to a predetermined epitope of the membrane protein or a membrane protein fragment.
44. The method of claim 43, wherein the assessment of the relative presence or absence of at least one species of membrane protein fragment on the cell surface further comprises determining a ratio of the detection signals of at least two labeled antibodies specific for at least two different epitopes of the membrane protein or a membrane protein fragment.
45. The method of claim 1, wherein the agent is an allosteric effector of the membrane protein.
46. The method of claim 1, wherein the detecting altered processing of the membrane protein on the surface of the host cell comprises the use of a flow sorter.
47. A method for identifying a peptide that alters processing of an angiotensin converting enzyme (ACE) membrane protein comprising: introducing an expression library comprising a plurality of oligonucleotides, at least a majority of the oligonucleotides having different sequences encoding different peptides, into a first plurality of animal host cells that express ACE membrane protein and at least one ACE processing enzyme, the host cells thereby expressing and displaying the different peptides within a secretory pathway and on an extracellular cell surface; selecting from the first plurality of host cells displaying the different peptides a first subset of host cells that exhibit altered ACE processing;STDC0234 and identifying from the first subset of host cells a first sub-library of the expression library comprising at least one oligonucleotide that encodes the peptide that <Desc/Clms Page number 60> alters the processing of ACE.
48. The method of claim 47, wherein the animal host cell is a mammalian host cell.
49. The method of claim 47, wherein the animal host cell is a recombinant host cell.
50. The method of claim 47, wherein the animal host cell is an isolated cell.
51. The method of claim 47, wherein the first plurality of host cells display the different peptides under substantially physiological conditions.
52. A method for identifying a peptide that alters processing of ACE membrane protein comprising: pre-enriching an expression library comprising a plurality of oligonucleotides, at least a majority of the oligonucleotides having different sequences encoding different peptides, for at least one oligonucleotide that encodes a peptide that specifically binds to ACE, the pre-enrichment comprising the steps of introducing the expression library into a phage display vector which can express the peptides encoded by the oligonucleotide sequences on the surface of the phage; expressing the different peptides on the surface of the phage; selecting a subset of phage particles that express peptides that specifically bind ACE membrane protein;STDC0879 recovering the oligonucleotide sequences from the selected phage particles to form a pre-enriched expression library introducing the pre-enriched expression library into a first plurality of animal host cells that express ACE membrane protein and at least one ACE membrane protein processing enzyme, the host cells thereby expressing and displaying the at least one ACE-binding peptide within a secretory pathway and on an extracellular cell surface; <Desc/Clms Page number 61> selecting from the first plurality of host cells displaying the at least one ACE membrane protein-binding peptide a first subset of host cells that exhibit altered ACE processing; and identifying from the first subset of host cells a first sub-library of the pre- enriched expression library comprising at least one oligonucleotide that encodes the peptide that alters the processing of ACE.
53. A method for identifying a peptide that alters processing of ACE membrane protein comprising: introducing an expression library comprising a plurality of oligonucleotides, at least a majority of the oligonucleotides having different sequences encoding different peptides, into a first plurality of animal host cells that express ACE membrane protein and at least one ACE membrane protein processing enzyme, the host cells thereby expressing and displaying the different peptides within a secretory pathway and on an extracellular cell surface; selecting from the first plurality of host cells displaying the different peptides a first subset of host cells that exhibit altered ACE processing;STDC0603 wherein the altered ACE processing is determined by assessing the relative presence or absence of at least one species of ACE released from the surface of the host cells displaying the different peptides by contacting the host cells with at least one detectably labeled marker that specifically binds to the at least one species of ACE fragment and detecting the bound labeled marker; and identifying from the first subset of host cells a first sub-library of the expression library comprising at least one oligonucleotide that encodes the peptide that alters the processing of ACE membrane protein.
54. A method for identifying a peptide that alters processing of ACE membrane protein comprising: introducing an expression library comprising a plurality of oligonucleotides, at least a majority of the oligonucleotides having different sequences encoding different peptides, into a first plurality of animal host cells that express ACE <Desc/Clms Page number 62> membrane protein and at least one ACE processing enzyme, the host cells thereby expressing and displaying the different peptides within a secretory pathway and on an extracellular cell surface under substantially physiological conditions ; selecting from the first plurality of host cells displaying the different peptides a first subset of host cells that exhibit altered ACE processing;STDC0627 wherein the altered ACE processing is determined by assessing the relative presence or absence of at least one species of ACE fragment on the surface or released from the surface of the host cells displaying the different peptides by contacting the host cells with at least one detectably labeled marker that specifically binds to the at least one species of ACE fragment and detecting the bound labeled marker; and identifying from the first subset of host cells a first sub-library of the expression library comprising at least one oligonucleotide that encodes the peptide that alters the processing of ACE membrane protein.